09:05 AM EDT, 09/19/2024 (MT Newswires) -- Alector ( ALEC ) said Thursday that the baseline characteristics of its phase 3 clinical trial evaluating latozinemab "suggest a representative study population" which "enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation."

Alector ( ALEC ) said the baseline clinical assessments show that the trial enrolled the intended population of participants with frontotemporal dementia. It added that this will allow the company to test its hypothesis that the drug candidate "may slow disease progression."

The biotech firm said it is developing the drug candidate with British pharmaceutical company GSK (GSK). Shares of Alector ( ALEC ) were up 3.2% in recent premarket activity.

Price: 5.82, Change: +0.18, Percent Change: +3.19